RSV – Medxy AI

RSV Frequently Precedes Influenza Peaks: Mapping the Temporal Sequence of the Post-Pandemic Triple-Threat in the United States

By MedXY 02/08/2026

A retrospective study of 148 state-level seasons reveals that RSV typically peaks three weeks before influenza, while COVID-19 lacks consistent seasonality, providing a critical framework for optimizing hospital resource allocation and vaccination timing.

Cardiology Infectious Diseases news

RSV-Related Hospitalization Linked to Surge in Acute Myocardial Infarction and Stroke Risk

By MedXY 02/06/2026

A large-scale study reveals that RSV hospitalization significantly increases the risk of myocardial infarction, stroke, and heart failure exacerbations, with the highest risk occurring within the first week post-admission, emphasizing the critical need for adult vaccination.

Infectious Diseases news Pediatrics

Nirsevimab Slashing Pediatric LRTI Hospitalizations by Over 60%: Real-World Evidence Supports Universal Immunization

By MedXY 12/24/2025

A comprehensive meta-analysis of over 260,000 infants confirms that nirsevimab significantly reduces respiratory syncytial virus (RSV) and lower respiratory tract infection (LRTI) hospitalizations and emergency department visits, providing a robust evidence base for pediatric immunization strategies.

Infectious Diseases news Pediatrics

Nirsevimab Outperforms Maternal Vaccination in Reducing Severe RSV Outcomes: Insights from Comparative Real-World Evidence

By MedXY 12/23/2025

Recent real-world data from the US and France indicate that while both maternal RSV vaccination and nirsevimab are effective, nirsevimab may offer superior protection against hospitalization and intensive care admission for infants in their first respiratory syncytial virus season.

Infectious Diseases news Public Health

IDSA 2025 Update: Stronger Flu and RSV Vaccine Recommendations for Immunocompromised People — What Clinicians Need to Know

By MedXY 11/23/2025

The Infectious Diseases Society of America now recommends annual high-dose or adjuvanted influenza vaccine and a single RSV dose for most immunocompromised persons; timing around immunosuppression and household immunization are emphasized.

news Pediatrics Respiratory

Nirsevimab Halves RSV Bronchiolitis Risk in Infants — High Effectiveness Sustained Despite Emergent RSV‑B Mutations

By MedXY 11/11/2025

A multicenter test-negative case-control study in France found high and sustained effectiveness of nirsevimab against RSV bronchiolitis in infants across two consecutive seasons (83.2% and 89.3%), despite emergence of RSV-B mutations.

Infectious Diseases news Pediatrics Respiratory

Nirsevimab Cuts RSV Lower Respiratory Infections in Infants Without Replacing Other Viruses: Post‑hoc Analysis of the Phase 3 MELODY Trial

By MedXY 11/10/2025

Post hoc analysis of the MELODY Phase 3 trial shows nirsevimab reduced RSV-associated lower respiratory tract infections and RSV coinfections in healthy term and late-preterm infants, with no signal of viral replacement by other respiratory pathogens.

Infectious Diseases news Pediatrics Public Health Respiratory

Nirsevimab in Chile’s First National RSV Campaign: 76% Reduction in RSV Hospitalisations and 85% Fewer ICU Admissions in Infants

By MedXY 11/10/2025

A nationwide retrospective study from Chile finds that a universal nirsevimab immunisation strategy in 2024 reduced RSV-related lower respiratory tract infection hospitalisations by 76% and ICU admissions by 85%, with an NNT of 35 to prevent one RSV LRTI admission.

Infectious Diseases news Pediatrics

Widespread Nirsevimab and Maternal RSV Vaccination Linked to Large Drop in Infant Hospitalizations in First Full Season

By MedXY 11/10/2025

Real-world surveillance from 2024–2025 shows substantial reductions in RSV-associated hospitalizations among infants after broad availability of maternal RSV vaccination and nirsevimab, with effectiveness estimates approximating those from pivotal trials.

Infectious Diseases news Pediatrics

Evolving Patterns of Clinical Testing for SARS-CoV-2, Influenza, and RSV in Hospitalized Youths (2016–2024): Insights and Implications

By MedXY 10/27/2025

This study evaluates clinical testing trends for COVID-19, influenza, and RSV among hospitalized children from 2016 to 2024, revealing shifts in testing frequency and identifying factors influencing test utilization.

Pediatrics Public Health Respiratory Specialties

Understanding RSV: Why Immunization Is a Game-Changer for Infants and Vulnerable Adults

By MedXY 09/29/2025

Respiratory Syncytial Virus (RSV) poses serious risks to infants and older adults. Since 2023, RSV immunizations have drastically reduced hospitalizations and deaths. This article explains RSV, symptoms, immunization options, and prevention strategies.

Infectious Diseases news Pediatrics Respiratory Specialties

Clesrovimab: A Promising Monoclonal Antibody for Preventing RSV in Healthy Infants

By MedXY 09/27/2025

A single dose of clesrovimab significantly reduces respiratory syncytial virus (RSV) infections and hospitalizations in healthy infants during their first RSV season, with a safety profile comparable to placebo.

Pediatrics Public Health Specialties

Maternal Bivalent Prefusion F RSV Vaccine Significantly Reduces Infant Hospitalisation in UK: Real-World Evidence from a Multicentre Study

By MedXY 08/22/2025

A UK-wide multicentre study shows maternal bivalent RSV prefusion F vaccination reduces infant hospitalisation for RSV-associated ALRI by up to 72%, confirming real-world effectiveness matching clinical trials.